CN1976720A - 用于治疗严重急性呼吸道综合征(sars)的组合物和方法 - Google Patents

用于治疗严重急性呼吸道综合征(sars)的组合物和方法 Download PDF

Info

Publication number
CN1976720A
CN1976720A CNA200480013748XA CN200480013748A CN1976720A CN 1976720 A CN1976720 A CN 1976720A CN A200480013748X A CNA200480013748X A CN A200480013748XA CN 200480013748 A CN200480013748 A CN 200480013748A CN 1976720 A CN1976720 A CN 1976720A
Authority
CN
China
Prior art keywords
tnf
sars
inhibitor
composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480013748XA
Other languages
English (en)
Chinese (zh)
Inventor
G·R·锡伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Publication of CN1976720A publication Critical patent/CN1976720A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA200480013748XA 2003-05-20 2004-05-20 用于治疗严重急性呼吸道综合征(sars)的组合物和方法 Pending CN1976720A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/441,059 2003-05-20
US10/441,059 US7892563B2 (en) 2003-05-20 2003-05-20 Methods for treatment of severe acute respiratory syndrome (SARS)

Publications (1)

Publication Number Publication Date
CN1976720A true CN1976720A (zh) 2007-06-06

Family

ID=33449934

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480013748XA Pending CN1976720A (zh) 2003-05-20 2004-05-20 用于治疗严重急性呼吸道综合征(sars)的组合物和方法

Country Status (14)

Country Link
US (2) US7892563B2 (https=)
EP (1) EP1624850A4 (https=)
JP (1) JP2007525465A (https=)
KR (1) KR20060023968A (https=)
CN (1) CN1976720A (https=)
AU (1) AU2004266111B8 (https=)
BR (1) BRPI0410467A (https=)
CA (1) CA2526431A1 (https=)
IL (1) IL171972A0 (https=)
MX (1) MXPA05012497A (https=)
NO (1) NO20056073L (https=)
NZ (1) NZ543655A (https=)
RU (1) RU2411042C2 (https=)
WO (1) WO2005018535A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228480A (zh) * 2020-02-24 2020-06-05 浙江正熙生物医药有限公司 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
CN113425722A (zh) * 2020-03-23 2021-09-24 上海市浦东新区公利医院(第二军医大学附属公利医院) 苦味受体激动剂及其在预防和治疗SARS-CoV-2相关传染病中的应用
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
CN116133657A (zh) * 2020-05-07 2023-05-16 4活性生物科技公司 治疗covid-19疾病的新组合物和方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
JP4845091B2 (ja) * 2005-08-09 2011-12-28 学校法人日本大学 コロナウィルスの遺伝子を切断するリボザイム
CA2651775A1 (en) * 2006-05-08 2008-05-08 University Of Virginia Patent Foundation Compositions and methods for treating anthrax lethality
AU2007272970C1 (en) * 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
KR101935072B1 (ko) * 2011-05-19 2019-01-03 모찌다 세이야쿠 가부시끼가이샤 오줌 검체를 사용한 호흡기 감염증의 진단
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
BR112022017986A2 (pt) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticorpos anticoronavírus e métodos de uso
WO2021186439A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US11648236B2 (en) * 2020-04-03 2023-05-16 Veru Inc. Methods of treating coronavirus
EP4132526A1 (en) * 2020-04-08 2023-02-15 Nostrum Pharmaceuticals, LLC Compositions and methods for the prophylaxis and/or treatment of viral infections or conditions associated therewith
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法
IL274327A (en) * 2020-04-28 2021-10-31 Zaltzman Pinchas Antiviral preparations
WO2021226437A1 (en) * 2020-05-07 2021-11-11 Bio-Rad Laboratories, Inc. Sars-cov-2 immunoassay and materials therefor
MX2022014083A (es) * 2020-05-15 2023-02-22 Altered Labs Llc Kit de tratamiento de suplemento de refuerzo inmunologico y metodos de uso.
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
US20220273641A1 (en) * 2020-10-07 2022-09-01 Vera Mikhailov Method for treating coronavirus infections including SARS-CoV-2
WO2022264097A1 (en) * 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4720489A (en) 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3650150T2 (de) 1985-08-16 1995-04-27 The Rockefeller University, New York, N.Y. Modulator der anabolischen Aktivität und seine Verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5196430A (en) 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
ES2072330T5 (es) 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2032191C (en) 1989-12-13 1999-05-18 David Wallach Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
DE4027616A1 (de) 1990-08-31 1992-03-05 Boehringer Mannheim Gmbh Verfahren zur bestimmung von polymerase-aktivitaet
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ATE190629T1 (de) 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
WO1993001211A1 (en) 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5547979A (en) 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
DE69502378T2 (de) 1994-01-20 1998-10-01 British Biotech Pharm Metalloproteinaseinhibitoren
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6107273A (en) 1995-01-24 2000-08-22 Thomas Jefferson University Tumor necrosis factor inhibitors
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
EP0912519A1 (en) 1996-05-20 1999-05-06 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US5883131A (en) 1997-07-09 1999-03-16 Pfizer Inc. Cyclic sulfone derivatives
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
MXPA00012842A (es) 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
WO2000009150A2 (en) 1998-08-17 2000-02-24 Prendergast Patrick T Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US6114517A (en) 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
SG101418A1 (en) * 1999-03-30 2004-01-30 Showa Denko Kk Production process for magnetic recording medium
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6632667B1 (en) * 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111228480A (zh) * 2020-02-24 2020-06-05 浙江正熙生物医药有限公司 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用
CN115996741A (zh) * 2020-03-11 2023-04-21 百欧林纳克斯有限公司 用于治疗急性呼吸窘迫综合征及病毒感染的cxcr4抑制剂
CN113425722A (zh) * 2020-03-23 2021-09-24 上海市浦东新区公利医院(第二军医大学附属公利医院) 苦味受体激动剂及其在预防和治疗SARS-CoV-2相关传染病中的应用
CN116133657A (zh) * 2020-05-07 2023-05-16 4活性生物科技公司 治疗covid-19疾病的新组合物和方法

Also Published As

Publication number Publication date
NZ543655A (en) 2009-07-31
CA2526431A1 (en) 2005-03-03
JP2007525465A (ja) 2007-09-06
WO2005018535A2 (en) 2005-03-03
WO2005018535A3 (en) 2006-12-21
US7892563B2 (en) 2011-02-22
AU2004266111B8 (en) 2010-12-23
US20060263847A1 (en) 2006-11-23
BRPI0410467A (pt) 2006-05-30
EP1624850A4 (en) 2007-10-31
AU2004266111A1 (en) 2005-03-03
NO20056073L (no) 2005-12-20
US20040235047A1 (en) 2004-11-25
MXPA05012497A (es) 2006-07-03
RU2005139730A (ru) 2006-05-10
US7722886B2 (en) 2010-05-25
RU2411042C2 (ru) 2011-02-10
EP1624850A2 (en) 2006-02-15
KR20060023968A (ko) 2006-03-15
AU2004266111B2 (en) 2010-08-26
IL171972A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
CN1976720A (zh) 用于治疗严重急性呼吸道综合征(sars)的组合物和方法
TWI784988B (zh) 治療發炎症狀的方法
US8318172B2 (en) Breaking immunological tolerance with a genetically encoded unnatural amino acid
Pease et al. Chemokine receptor antagonists
AU772949B2 (en) Antibodies to human IL-1beta
JP2022019747A (ja) Ｂ型肝炎感染症の治療用のｐａｐｄ５阻害剤及びｐａｐｄ７阻害剤
CN1379815A (zh) Baff受体(bcma),一种免疫调节剂
CN1409639A (zh) 应用TNF－α拮抗剂和LFA－1拮抗剂治疗LFA－1或TNF－α介导的疾病
CN1863546A (zh) 用可溶性ctla4分子治疗心血管疾病的方法
JP2009543579A (ja) 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
CN1295482A (zh) 炎性介质拮抗剂
EP0914157A1 (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
CN1787837A (zh) 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
JP2023025173A (ja) 抗ｉｌ２３特異的抗体で乾癬を治療する方法
CN1250286C (zh) Il－18抑制剂在治疗和/或预防动脉粥样硬化中的应用
CN1342165A (zh) 神经营养生长因子
Liu et al. Interleukin-6 in rheumatoid arthritis-from the laboratory to the bedside
AU2004209967A1 (en) Methods for modulating an inflammatory response
CN1323223A (zh) 通过阻断淋巴毒素β途径逆转病毒引起的系统休克和呼吸窘迫
JP6890340B2 (ja) グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法
JP2021525761A (ja) Ｂ型肝炎ウイルス感染を治療するための併用療法
KR20230011295A (ko) 암 치료에 사용하기 위한 조성물 및 방법
US20220389089A1 (en) Anti-il-27 antibodies and uses thereof
AU5182500A (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
CN1148381C (zh) 新的人趋化因子巨噬细胞炎性蛋白、其编码序列及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070606